SCHEMBL24976756

SCHEMBL24976756

CNC(=O)c1ccc(-c2ccc(Cl)cc2)nc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.72
KDR P35968 3/20 0.50
BRAF P15056 2/20 0.50
HPGDS O60760 1/20 0.47
RXFP1 Q9HBX9 2/20 0.47
NPC1 O15118 1/20 0.46
LDHA P00338 1/20 0.46
GPR119 Q8TDV5 1/20 0.46
NR4A2 P43354 1/20 0.45
ATM Q13315 1/20 0.45
P4HTM Q9NXG6 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DEGS1 O15121 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
PTPN11 Q06124 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
HTR2C P28335 1/20 0.44
MCHR1 Q99705 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15507078 0.86 BAZ2B (0.79) BAZ2BHPGDSRXFP1NPC1LDHA
SCHEMBL1542986 0.84 BAZ2B (1.00) BAZ2BHPGDSNPC1LDHAATM
SCHEMBL7962334 0.83 BAZ2B (0.74) BAZ2BHPGDSP4HTMSMN1; SMN2MAPT
SCHEMBL20057794 0.82 BAZ2B (0.68) BAZ2BHPGDSRXFP1NPC1LDHA
SCHEMBL4412321 0.81 MAPT (0.55) BAZ2BHPGDSRXFP1NPC1LDHA
SCHEMBL5648046 0.80 LDHA (0.71) BAZ2BRXFP1NPC1LDHAP4HTM
SCHEMBL1132053 0.79 HDAC2 (0.57) KDRNPC1SMN1; SMN2DEGS1GAA
SCHEMBL12409679 0.79 BAZ2B (0.65) BAZ2BRXFP1NPC1ATMSMN1; SMN2
SCHEMBL11009430 0.79 MAP4K4 (0.60) HPGDSRXFP1NPC1LDHASMN1; SMN2
SCHEMBL13876398 0.78 SMN1; SMN2 (0.54) BAZ2BHPGDSNPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof AMGEN INC. (US) 2023-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof CYP3A7, CYP51A1, NT5C3B BAZ2B 3384/4885KDR 3225/4885BRAF 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.